Why the study?
Does sacubitril/valsartan reduce sNEP activity and alter natriuretic peptide metabolism in patients with chronic heart failure?
Does sacubitril/valsartan reduce sNEP activity and alter natriuretic peptide metabolism in patients with chronic heart failure?
Sacubitril/valsartan exerts a pleiotropic favorable impact on the metabolism of heart failure patients, primarily affecting ANP rather than BNP.
Answers are grounded in this paper and cite their sources.
Supports pleiotropic metabolic effects of sacubitril/valsartan in HF; leaves open whether ANP predominance improves outcomes.
Sacubitril/valsartan rapidly and strongly reduced sNEP activity, leading to an increase in levels of NEP substrates. These data suggest a pleiotropic favourable impact of sacubitril/valsartan on the metabolism of HF patients with ANP rather than BNP as major effectors amongst natriuretic peptides.
No takes yet. Share an insight, caveat, or question.
Nougue et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: